Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Code Application Process
Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Code Application Process
The Company looks forward to providing more information as it becomes available on the unique permanent CPT and HCPCS codes and on expanding its distribution partners across the U.S. for its Venowave device.Toronto, Ontario--(Newsfile Corp. - August 22, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that the Company has heard back from the Centers for Medicare and Medicaid Services (CMS) on its application for the nine (9) unique permanent Current Procedural Terminology (CPT) / Healthcare Common Procedure Coding System (HCPCS) codes.
安大略省多倫多-(Newsfile Corp.-2023年8月22日)-Therma Bright Inc.(TSXV：THRM)(OTCQB：TBRIF)(以下簡稱“Therma”或“公司”)今天宣佈，公司已收到聯盟醫療保險和醫療補助服務中心(CMS)關於其申請九(9)個唯一的永久當前程式術語(CPT)/醫療保健通用程式編碼系統(HCPCS)代碼的反饋。
The Centers for Medicare and Medicaid Services (CMS) has asked the Company to secure approval from the U.S. Food and Drug Administration (FDA) through an updated 510K application that the Venowave device can be used successively by multiple patients along with additional changes. These updated changes to Therma Bright's 510k application are required for securing the permanent Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes.
醫療保險和醫療補助服務中心(CMS)要求該公司通過更新的510K應用程式獲得美國食品和藥物管理局(FDA)的批准，即Venowave設備可以在進行額外更改的情況下由多名患者連續使用。Therma Bright的510k應用程式的這些更新更改是保護永久當前程式術語(CPT)和醫療保健通用程式編碼系統(HCPCS)代碼所必需的。
"We are pleased that the Centers for Medicare and Medicaid Services (CMS) has provided us time to secure a permanent code for a specific designation through an updated 510K application through the FDA. Once that is complete, we will resubmit our application for the permanent CPT and HCPCS codes to CMS," shared Rob Fia, CEO of Therma Bright. "In the meantime, the Company continues shipping Venowave devices to its U.S. distributor network and encourages each partner to continue using the nine (9) temporary CPT and HCPCS codes for reimbursement, which are still viable and helping Medicaid and Medicare patients receive their much-needed reimbursements."
Therma Bright首席執行官羅布·菲亞分享道：“我們很高興，醫療保險和醫療補助服務中心(CMS)為我們提供了時間，通過FDA更新的510K應用程式，為特定的指定確保永久代碼。一旦完成，我們將向CMS重新提交永久CPT和HCPCS代碼的申請，”Therma Bright首席執行官Rob FIA分享道。與此同時，該公司繼續向其美國經銷商網路發運Venowave設備，並鼓勵每個合作夥伴繼續使用九(9)個臨時CPT和HCPCS代碼進行報銷，這些代碼仍然可行，可以幫助Medicaid和Medicare患者獲得他們急需的報銷。
The Company looks forward to providing more information as it becomes available on the unique permanent CPT and HCPCS codes and on expanding its distribution partners across the U.S. for its Venowave device.
該公司期待著在獲得唯一的永久CPT和HCPCS代碼以及擴大其Venowave設備在美國各地的分銷夥伴方面提供更多資訊。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
關於Therma Bright Inc.
Therma Bright是一家領先的專有診斷和醫療設備技術的開發商和合作夥伴，致力於為消費者和醫療專業人員提供高質量的創新解決方案，以應對當今一些最重要的醫療和保健挑戰。Therma Bright Inc.在多倫多證券交易所(TSXV：THRM)(場外交易市場代碼：TBRIF)(紐約證券交易所代碼：JNX)交易。參觀：。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Therma Bright Inc.
羅布·菲亞，首席執行官
郵箱：rfia@thermabright.com
Follow us on Twitter
關注我們的推特
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the commercialization and sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性陳述
本新聞稿中的某些陳述構成“前瞻性”陳述。這些陳述涉及未來的事件，如新聞稿中描述的Venowave和相關技術的商業化和銷售。所有這些陳述都涉及大量已知和未知的風險、不確定因素和其他因素，這些風險、不確定因素和其他因素可能導致實際結果與這些前瞻性陳述明示或暗示的結果大不相同。前瞻性陳述涉及重大風險和不確定因素，不應被解讀為對未來業績或結果的保證，也不一定是能否實現此類結果的準確跡象。由於幾個因素和風險，實際結果可能與預期大不相同。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為本新聞稿發佈之日的合理假設，但公司不能向投資者保證實際結果將與這些前瞻性陳述一致。本新聞稿中包含的前瞻性陳述是自本新聞稿發佈之日起作出的，除非適用的證券法規另有要求，否則公司不會因為新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述的意圖或義務。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。